Poseida Therapeutics — Technical Presentation (February 2022)
6 slides from Poseida Therapeutics's technical presentation, Feb 17, 2022
Slide 1: Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With mCRPC
Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY Exhibit 99.2
Slide 2: Phase 1 mCRPC Clinical Trial: P-PSMA-101-001
Phase 1 mCRPC Clinical Trial: P-PSMA-101-001 Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY Enrollment Day 0 Leukapheresis Baseline assessments Safety, efficacy, and biomarker assessments Lymphodepletion P-PSMA-101 infusion Week 2 Inpatient monitoring PD or 2 years to LT
Slide 3: Treatment-Emergent Adverse Events
TEAEs (n=14) TRAEs (n=14) Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY a Grade ≥3 events were 2 cases of macrophage activation syndrome/CRS, one fatal after non-compliance in follow-up. CRS was frequently associated with transaminitis and intermittently with ocular sy
Slide 4: Efficacy: Exceptional Antitumor Responses at the Lowest Dose Levels
g f Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY Efficacy: Exceptional Antitumor Responses at the Lowest Dose Levels a Central or local results. b CTC0 (n=5) defined as patients with CTCs >0 at enrollment and CTC = 0 at a post-infusion CTC assessment (12–13-week follo
Slide 5: Patient 220-003: Evidence of Near-Complete Tumor Elimination
Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY 105 40 30 20 10 0 104 102 50 103 -70 0 20 40 60 80 100 120 140 160 180 200 220 240 Days after infusion PSA (ng/mL) P-PSMA-101/µg DNA P-PSMA-101 copies/µg DNA in peripheral blood P-PSMA-101 copies/µg DNA in biopsy tissue PSA
Slide 6: Conclusions
This interim update shows the exceptional efficacy of novel anti-PSMA CAR-T-cell product. P-PSMA-101 at very low doses induced durable biochemical, radiographic, and functional radiographic responses in heavily pretreated patients with mCRPC, including a pathologic complete response, with notable PF
Poseida Therapeutics — Technical Presentation (February 2022) on 6ix